4.5 Article

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry

出版社

ELSEVIER
DOI: 10.1016/j.jchromb.2010.03.010

关键词

Gefitinib; Erlotinib; Sunitinib; Sorafenib; LC-MS/MS; Analysis

向作者/读者索取更多资源

A fast, sensitive, universal and accurate method for the determination of four different tyrosine kinase inhibitors from biological material was developed using LC-MS/MS techniques. Utilizing a simple protein precipitation with acetonitrile a 20 pi sample volume of biological matrixes can be extracted at 4 C with minimal effort. After centrifugation the sample extract is introduced directly onto the LC-MS/MS system without further clean-up and assayed across a linear range of 1-4000 ng/ml. Chromatography was performed using a Dionex Ultimate 3000 with a Phenomenex prodigy ODS3 (2.0 mm x 100 mm, 3 mu m) column and eluted at 200 mu l/min with a tertiary mobile phase consisting of 20 mM ammonium acetate:acetonitrile:methanol (2.5:6.7:8.3%). Injection volume varied from 0.1 mu l to 1 mu l depending on the concentration of the drug observed. Samples were observed to be stable for a maximum of 48 h after extraction when kept at 4 degrees C. Detection was performed using a turbo-spray ionization source and mass spectrometric positive multi-reaction-monitoring-mode (+MRM) for Gefitinib (447.1 m/z; 127.9 m/z), Erlotinib (393.9 m/z; 278.2 m/z), Sunitinib (399.1 m/z; 283.1 m/z) and Sorafenib (465.0 m/z; 251.9 m/z) at an ion voltage of +3500V. The accuracy, precision and limit-of-quantification (LOQ) from cell culture medium were as follows: Gefitinib: 100.2 +/- 3.8%. 11.2 nM; Erlotinib: 101.6 +/- 3.7%, 12.7 nM; Sunitinib: 100.8 +/- 4.3%, 12.6 nM; Sorafenib: 93.9 +/- 3.0%, 10.8 nM, respectively. This was reproducible for plasma, whole blood, and serum. The method was observed to be linear between the LOQand 4000 ng/ml for each analyte. Effectiveness of the method is illustrated with the analysis of samples from a cellular accumulation investigation and from determination of steady state concentrations in clinically treated patients. (C) 2010 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs: Exploring Potential Mechanisms of Resistance

Marika Franczak, Isabel Toenshoff, Gerrit Jansen, Ryszard T. Smolenski, Elisa Giovannetti, Godefridus J. Peters

Summary: Mitochondria are crucial for cancer cells as they play a significant role in their energy requirements and chemoresistance. Differences in energy metabolism, such as higher NAD(+) levels, the Warburg effect, and increased one-carbon metabolism, have been identified between cancer and normal cells. Targeting these metabolic pathways could be a promising approach for developing new anticancer drugs. Combining novel drugs with conventional agents may provide effective treatments for cancer.

CURRENT MEDICINAL CHEMISTRY (2023)

Article Oncology

Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo

M. Houweling, U. K. Abdul, C. Brahm, T. Lagerweij, S. Heukelom, P. W. Koken, R. Honeywell, L. E. Wedekind, G. J. Peters, H. Verheul, P. Sminia, D. Noske, T. Wurdinger, B. A. Westerman

Summary: This study investigated the radio-sensitizing effect of MEK inhibitor PD0325901 in in vitro and in vivo models of glioblastoma (GBM). The results showed that both MEK inhibitors had an in vitro radio-sensitizing effect, but no significant interaction between PD0325901 MEK inhibition and irradiation was observed in in vivo experiments.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)

Alessandro Gregori, Cecilia Bergonzini, Mjriam Capula, Giulia Mantini, Fatemeh Khojasteh-Leylakoohi, Annalisa Comandatore, Ghazaleh Khalili-Tanha, Alireza Khooei, Luca Morelli, Amir Avan, Erik H. Danen, Thomas Schmidt, Elisa Giovannetti

Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and chemoresistant cancer, with a stiff stroma surrounding it playing a role in chemoresistance. High expression of the mechanical sensor ITGA2 correlated with a poor prognosis in PDAC patients, and increased matrix stiffness led to the expression of ITGA2 and chemoresistance to gemcitabine. ITGA2 could be a potential therapeutic target to overcome gemcitabine resistance.

CANCERS (2023)

Review Biochemistry & Molecular Biology

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

Federica Borea, Marika A. Franczak, Maria Garcia, Matteo Perrino, Nadia Cordua, Ryszard T. Smolenski, Godefridus J. Peters, Rafal Dziadziuszko, Armando Santoro, Paolo A. Zucali, Elisa Giovannetti

Summary: Malignant Pleural Mesothelioma (MPM) is a rare neoplasm that is usually diagnosed at an advanced stage and requires systemic treatment due to its ineligibility for radical surgery. Chemotherapy has been the standard treatment for 20 years until immune checkpoint inhibitors were introduced. However, the prognosis remains poor, and targeted therapies for MPM have mostly failed in clinical trials. This review aims to explore the potential reasons for treatment failures and determine the need for further research in this area.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

Calogera Claudia Spagnolo, Giuliana Ciappina, Elisa Giovannetti, Andrea Squeri, Barbara Granata, Chiara Lazzari, Giulia Pretelli, Giulia Pasello, Mariacarmela Santarpia

Summary: In recent years, the development of therapeutic agents targeting actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC) has increased. Selective inhibitors, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have shown promising results in patients with MET deregulation, specifically exon 14 skipping mutations or MET amplification. This review provides an overview of MET signaling pathways, oncogenic alterations, laboratory techniques for detection, clinical data and ongoing studies on MET inhibitors, resistance mechanisms, and potential strategies for improving outcomes in MET-exon 14-altered NSCLC patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma

Marika A. Franczak, Oliwia Krol, Gabriela Harasim, Agata Jedrzejewska, Nadia Zaffaroni, Carlotta Granchi, Filippo Minutolo, Amir Avan, Elisa Giovannetti, Ryszard T. Smolenski, Godefridus J. Peters

Summary: Malignant mesothelioma (MM) is a highly aggressive and resistant tumor. In this study, the cytotoxicity of new inhibitors of glucose transporter type 1 (GLUT-1) and lactate dehydrogenase-A (LDH-A) in relation to ATP/NAD+ metabolism, glycolysis and mitochondrial respiration was investigated. The inhibitors showed cytotoxicity in MM cells, associated with a decrease in ATP and NAD+, and were most effective in cells with the highest metabolic modulation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Oncology

Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma

Mahrou Vahabi, Bilal Dehni, Ines Antomas, Elisa Giovannetti, Godefridus J. Peters

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited improvement in mortality rate despite extensive research and clinical trials. There is a need for comprehensive molecular characterization to identify biomarkers for early detection and evaluation of treatment response. MicroRNAs (miRNAs) show promise as stable biomarkers that can be detected in fixed tissues and biofluids, and their deregulation plays a role in the oncogenesis and metastasis of PDAC. Several oncomiRs and TsmiRs have been identified that contribute to chemoresistance in PDAC, and miRNA-based therapy approaches have shown success in vivo. Integrating miRNAs in PDAC treatment holds potential for personalized medicine.

CANCER AND METASTASIS REVIEWS (2023)

Review Biochemistry & Molecular Biology

Role of exosomes in transferring chemoresistance through modulation of cancer glycolytic cell metabolism

Mahrou Vahabi, Annalisa Comandatore, Marika A. Franczak, Ryszard T. Smolenski, Godefridus J. Peters, Luca Morelli, Elisa Giovannetti

Summary: Exosomes play a crucial role in intercellular communication and can influence cancer cell behavior and response to treatment. They can transport glycolytic enzymes, leading to altered glucose metabolism and increased tumor progression, survival, immune evasion, and drug resistance. Understanding exosome-mediated cell-to-cell communication may open new therapeutic avenues and facilitate biomarker development, and combining exosome-based-targeted therapies with existing treatments holds promise in overcoming resistance and improving cancer treatment outcomes.

CYTOKINE & GROWTH FACTOR REVIEWS (2023)

Article Oncology

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne

Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu

Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Chemistry, Medicinal

1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1

Daniela Carbone, Camilla Pecoraro, Giovanna Panzeca, Geng Xu, Margot S. F. Roeten, Stella Cascioferro, Elisa Giovannetti, Patrizia Diana, Barbara Parrino

Summary: A series of new nortopsentin analogs were successfully synthesized by replacing the central imidazole ring with a 1,3,4-oxadiazole or 1,3,4-thiadiazole moiety. The antiproliferative activity of these derivatives was evaluated against pancreatic cancer cell lines, showing significant reduction in cell migration. Cell cycle analysis indicated cell cycle arrest and inhibition of CDK1 activity, a crucial regulator of cell cycle progression and cancer cell proliferation.

MARINE DRUGS (2023)

Article Oncology

Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models

Maryam Alaei, Seyedeh Elnaz Nazari, Ghazaleh Pourali, AliReza Asadnia, Mehrdad Moetamani-Ahmadi, Hamid Fiuji, Hamid Tanzadehpanah, Fereshteh Asgharzadeh, Fatemeh Babaei, Fatemeh Khojasteh-Leylakoohi, Ibrahim Saeed Gataa, Mohammad Ali Kiani, Gordon A. Ferns, Alfred King-yin Lam, Seyed Mahdi Hassanian, Majid Khazaei, Elisa Giovannetti, Amir Avan

Summary: In this study, the potential of targeting the enzyme cytochrome P450 (CYP450) using lopinavir/ritonavir in colorectal cancer (CRC) was explored. Experimental methods were employed to assess the effects of lopinavir/ritonavir on CRC, and it was found that inhibiting CYP450 reduced cell proliferation, induced cell death, and suppressed cell migration. Lopinavir/ritonavir also inhibited tumor growth and fibrosis. These findings suggest that targeting CYP450 with lopinavir/ritonavir has therapeutic potential in CRC and further research in this area is needed.

CANCERS (2023)

Article Oncology

The Prognostic Value of ASPHD1 and ZBTB12 in Colorectal Cancer: A Machine Learning-Based Integrated Bioinformatics Approach

Alireza Asadnia, Elham Nazari, Ladan Goshayeshi, Nima Zafari, Mehrdad Moetamani-Ahmadi, Lena Goshayeshi, Haneih Azari, Ghazaleh Pourali, Ghazaleh Khalili-Tanha, Mohammad Reza Abbaszadegan, Fatemeh Khojasteh-Leylakoohi, Mohammadjavad Bazyari, Mir Salar Kahaei, Elnaz Ghorbani, Majid Khazaei, Seyed Mahdi Hassanian, Ibrahim Saeed Gataa, Mohammad Ali Kiani, Godefridus J. Peters, Gordon A. Ferns, Jyotsna Batra, Alfred King-yin Lam, Elisa Giovannetti, Amir Avan

Summary: This study identified genetic variants and differentially expressed genes in colorectal cancer patients using genome-wide DNA and RNA sequencing. ASPHD1 and ZBTB12 genes were identified as potential prognostic markers, and two novel genetic variants were found to potentially regulate gene expression. These findings provide a proof of concept for the evaluation of emerging biomarkers in colorectal cancer.

CANCERS (2023)

暂无数据